ZLCS News 1.20 Zalicus Inc (ZLCS)
Post# of 273256
Posted On: 04/17/2014 4:40:25 PM
Zalicus Inc (ZLCS) 1.20 $ZLCS
SHAREHOLDER ALERT: Brower Piven Announces the Investigation of Zalicus, Inc. over the Proposed Merger with Epirus Biopharmaceuticals, Inc.
Business Wire - Wed Apr 16, 3:50PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty to current shareholders of Zalicus, Inc. ("Zalicus" or the "Company"
(NasdaqCM: ZLCS) and other violations of state law by the board of directors of Zalicus relating to the proposed merger of the Company with Epirus Biopharmraceuticals, Inc. ("Epirus" .
Most active Nasdaq-traded stocks
AP - Wed Apr 16, 12:30PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of Zalicus, Inc. - ZLCS
PR Newswire - Wed Apr 16, 11:51AM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Zalicus, Inc. ("Zalicus" or the "Company" (Nasdaq: ZLCS) relating to the proposed merger with Epirus Biopharmaceuticals, Inc. ("Epirus" .
Stock to Watch: Zalicus Up 39.8% (ZLCS)
Comtex SmarTrend(R) - Wed Apr 16, 10:09AM CDT
Zalicus (NASDAQ:ZLCS) is one of today's best performing low-priced stocks, up 39.8% to $1.44 on 25.1x average daily volume. Zalicus has traded 9.0 million shares thus far today, vs. average volume of 360,000 shares per day. The stock has outperformed the Dow (39.8% to the Dow's 0.4%) and outperformed the S&P 500 (39.8% to the S&P's 0.3%) during today's trading.
Why Zalicus (ZLCS) Stock Is Soaring Today
at The Street - Wed Apr 16, 9:47AM CDT
Zalicus (ZLCS) soared Wednesday after the biopharmaceutical company announced it would merge with Epirus Biopharmaceuticals. After the all-stock transaction closes, Zalicus will be known as Epirus and will operate under the latter company's...
Epirus Closes $36 Million Series B Financing
Business Wire - Wed Apr 16, 6:01AM CDT
Epirus Biopharmaceuticals, Inc. (Epirus), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, today announced that it has closed a $36 million Series B financing round led by Livzon Mabpharm, Inc. Other investors participating in this round include Adage Capital, Greenwoods Investment, Gibralt US, Inc., Monashee Capital Partners LP, and an investment affiliate of Mousse Partners, as well as existing investors TPG Biotech(R), Montreux Equity Partners and 5AM Ventures. In conjunction with the financing, Daotian Fu, Ph.D., CEO of Livzon Mabpharm, Inc., joined the Epirus board of directors. Leerink Partners LLC acted as a placement agent for the transaction.
Epirus and Zalicus Announce Merger Agreement
Business Wire - Wed Apr 16, 6:01AM CDT
--Epirus closes $36 million Series B financing round
Zalicus and Epirus Announce Merger Agreement
Business Wire - Wed Apr 16, 6:01AM CDT
--Epirus Closes $36 Million Series B Financing Round
Global Pain Management Drugs Market 2014-2018 with Abbott Labs, Eli Lilly, Endo Health Solutions, Pfizer & Purdue Pharma Dominating
M2 - Fri Apr 11, 4:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bjv7jj/global_pain) has announced the addition of the "Global Pain Management Drugs Market 2014-2018 with Abbott Labs, Eli Lilly, Endo health Solutions, Pfizer & Purdue Pharma Dominating" report to their offering. The Global Pain Management Drugs market will grow at a CAGR of 3.84 percent over the period 2013-2018. One of the main drivers in this market is the increase in global aging population. The rise in aging population has consequently led to an increase in the incidence of diseases such as chronic arthritis, diabetic neuropathy, osteoarthritis, and cancer. R&D activities are increasing due to the strong need for new efficacious and better-tolerated medications. Developing better pain treatments is the main goal of all pain research being conducted by various institutes. Morphine is one such drug that works through the body's natural pain-killing machinery, preventing pain messages from reaching the brain. Patients receiving morphine also face the problem of morphine tolerance. Scientists are working toward the development of a morphine-like drug that will have the pain-deadening qualities of morphine but without the drug's negative side effects, such as sedation and the potential for addiction. Further, the report states that one of the main challenges is the increase in generic competition. The patent expiry of a drug results in the loss of the exclusive market for that drug, leading to a rapid decline in sales. The key vendors dominating this space are: - Abbott Laboratories - Eli Lilly and Co. - Endo Health Solutions Inc. - Pfizer Inc. - Purdue Pharma L.P. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Category - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis Other Companies Featured: - Actavis plc - Allergen Inc. - Astra Zenca plc - Baxter International Inc. - Bayer Healthcare AG - Boehringer Ingelheim GmbH - Boston Scientific Corp. - Bristol Myers Squibb Co. - Durect Corp. - F. Hoffmann La Roche Ltd. - Forest Laboratories Inc. - GlaxoSmithKline plc - Hospira Inc. - Johnson & Johnson - Merck & Co. Inc. - Novartis AG - Pain Therapeutics Inc. - Sanofi S.A. - St. Jude Medical Inc. - UCB S.A. - Valeant Pharmaceuticals International Inc. - Zalicus Inc. For more information visit http://www.researchandmarkets.com/research/bj...lobal_pain
Zalicus to Present at AACR 2014 Annual Meeting
Business Wire - Tue Apr 01, 7:30AM CDT
Zalicus Inc. (Nasdaq Global Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that a poster developed in collaboration with colleagues from Eisai Inc. and a podium presentation with collaborators from Sanofi will be given at the American Association for Cancer Research (AACR) 2014 Annual Meeting which takes place April 5-9, 2014 in San Diego, CA. These preclinical data, which were generated in separate studies by leveraging the Zalicus combination High-throughput screening (cHTS(TM)) technology platform, demonstrate the potential to identify (or highlight) synergistic activity of the Eisai nontaxane eribulin and the Sanofi antibody drug conjugate SAR3419, through drug combinations.
Zalicus Reports Financial Results for the Fourth Quarter and Year-End 2013
Business Wire - Thu Mar 13, 6:30AM CDT
Zalicus Inc. (Nasdaq Capital Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today reported financial results for the fourth quarter and year ended December 31, 2013.
Canadian Forex Review: C$ Strengthens
Commodity News Service Canada - Commodity News Service Canada, Inc. - Wed Feb 12, 3:44PM CST
The Canadian dollar strengthened against the US dollar on Wednesday amid positive Chinese trade data, analysts said.
Hot Stock: Zalicus, Shares Gain 11.5% (ZLCS)
Comtex SmarTrend(R) - Wed Jan 22, 10:11AM CST
Zalicus (NASDAQ:ZLCS) is one of today's best performing low-priced stocks, up 11.5% to $2.14 on 3.1x average daily volume. Thus far today, Zalicus has traded 4.3 million shares, vs. average volume of 1.4 million shares per day. The stock has outperformed the Dow (25.9% to the Dow's -0.4%) and outperformed the S&P 500 (25.9% to the S&P's -0.1%) during today's trading.
3 Stocks Under $10 in Breakout Territory
at The Street - Wed Jan 22, 6:00AM CST
These under-$10 stocks are within range of triggering major breakout trades.
Traders Get Bullish on Shares of Zalicus, Shares Up 8.6% (ZLCS)
Comtex SmarTrend(R) - Fri Jan 17, 12:47PM CST
Zalicus (NASDAQ:ZLCS) is one of today's best performing low-priced stocks, up 8.6% to $1.76 on 1.1x average daily volume. Zalicus has traded 1.5 million shares thus far today, vs. average volume of 1.4 million shares per day. The stock has outperformed the Dow (8.6% to the Dow's 0.3%) and outperformed the S&P 500 (8.6% to the S&P's -0.2%) during today's trading.
Preliminary Results, Conferences, Stock Price Movements, and Acquisitions - Research Report on Community Health, ArthroCare, NuPathe, Zalicus, and Neogen
PR Newswire - Mon Jan 13, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
5 Stocks Under $10 Set to Soar
at The Street - Fri Jan 10, 6:00AM CST
These under-$10 stocks look ready to trade higher from current levels.
Biotech Trading 2014 Starts Hot, But Surprise, Last Year Was Even Better
at The Street - Thu Jan 09, 10:13AM CST
The biotech sector has jumped off to a strong start to 2014, with today's blockbuster move in Intercept Pharma offering a big assist. I know it's ridiculously early to make any sort of definitive judgment, but I wondered how the first days of biotech...
5 Stocks Poised for Breakouts
at The Street - Fri Jan 03, 2:19PM CST
These stocks look ready to break out and trade higher from current levels.
SHAREHOLDER ALERT: Brower Piven Announces the Investigation of Zalicus, Inc. over the Proposed Merger with Epirus Biopharmaceuticals, Inc.
Business Wire - Wed Apr 16, 3:50PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty to current shareholders of Zalicus, Inc. ("Zalicus" or the "Company"
(NasdaqCM: ZLCS) and other violations of state law by the board of directors of Zalicus relating to the proposed merger of the Company with Epirus Biopharmraceuticals, Inc. ("Epirus" . Most active Nasdaq-traded stocks
AP - Wed Apr 16, 12:30PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of Zalicus, Inc. - ZLCS
PR Newswire - Wed Apr 16, 11:51AM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Zalicus, Inc. ("Zalicus" or the "Company"
(Nasdaq: ZLCS) relating to the proposed merger with Epirus Biopharmaceuticals, Inc. ("Epirus" . Stock to Watch: Zalicus Up 39.8% (ZLCS)
Comtex SmarTrend(R) - Wed Apr 16, 10:09AM CDT
Zalicus (NASDAQ:ZLCS) is one of today's best performing low-priced stocks, up 39.8% to $1.44 on 25.1x average daily volume. Zalicus has traded 9.0 million shares thus far today, vs. average volume of 360,000 shares per day. The stock has outperformed the Dow (39.8% to the Dow's 0.4%) and outperformed the S&P 500 (39.8% to the S&P's 0.3%) during today's trading.
Why Zalicus (ZLCS) Stock Is Soaring Today
at The Street - Wed Apr 16, 9:47AM CDT
Zalicus (ZLCS) soared Wednesday after the biopharmaceutical company announced it would merge with Epirus Biopharmaceuticals. After the all-stock transaction closes, Zalicus will be known as Epirus and will operate under the latter company's...
Epirus Closes $36 Million Series B Financing
Business Wire - Wed Apr 16, 6:01AM CDT
Epirus Biopharmaceuticals, Inc. (Epirus), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, today announced that it has closed a $36 million Series B financing round led by Livzon Mabpharm, Inc. Other investors participating in this round include Adage Capital, Greenwoods Investment, Gibralt US, Inc., Monashee Capital Partners LP, and an investment affiliate of Mousse Partners, as well as existing investors TPG Biotech(R), Montreux Equity Partners and 5AM Ventures. In conjunction with the financing, Daotian Fu, Ph.D., CEO of Livzon Mabpharm, Inc., joined the Epirus board of directors. Leerink Partners LLC acted as a placement agent for the transaction.
Epirus and Zalicus Announce Merger Agreement
Business Wire - Wed Apr 16, 6:01AM CDT
--Epirus closes $36 million Series B financing round
Zalicus and Epirus Announce Merger Agreement
Business Wire - Wed Apr 16, 6:01AM CDT
--Epirus Closes $36 Million Series B Financing Round
Global Pain Management Drugs Market 2014-2018 with Abbott Labs, Eli Lilly, Endo Health Solutions, Pfizer & Purdue Pharma Dominating
M2 - Fri Apr 11, 4:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bjv7jj/global_pain) has announced the addition of the "Global Pain Management Drugs Market 2014-2018 with Abbott Labs, Eli Lilly, Endo health Solutions, Pfizer & Purdue Pharma Dominating" report to their offering. The Global Pain Management Drugs market will grow at a CAGR of 3.84 percent over the period 2013-2018. One of the main drivers in this market is the increase in global aging population. The rise in aging population has consequently led to an increase in the incidence of diseases such as chronic arthritis, diabetic neuropathy, osteoarthritis, and cancer. R&D activities are increasing due to the strong need for new efficacious and better-tolerated medications. Developing better pain treatments is the main goal of all pain research being conducted by various institutes. Morphine is one such drug that works through the body's natural pain-killing machinery, preventing pain messages from reaching the brain. Patients receiving morphine also face the problem of morphine tolerance. Scientists are working toward the development of a morphine-like drug that will have the pain-deadening qualities of morphine but without the drug's negative side effects, such as sedation and the potential for addiction. Further, the report states that one of the main challenges is the increase in generic competition. The patent expiry of a drug results in the loss of the exclusive market for that drug, leading to a rapid decline in sales. The key vendors dominating this space are: - Abbott Laboratories - Eli Lilly and Co. - Endo Health Solutions Inc. - Pfizer Inc. - Purdue Pharma L.P. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Category - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis Other Companies Featured: - Actavis plc - Allergen Inc. - Astra Zenca plc - Baxter International Inc. - Bayer Healthcare AG - Boehringer Ingelheim GmbH - Boston Scientific Corp. - Bristol Myers Squibb Co. - Durect Corp. - F. Hoffmann La Roche Ltd. - Forest Laboratories Inc. - GlaxoSmithKline plc - Hospira Inc. - Johnson & Johnson - Merck & Co. Inc. - Novartis AG - Pain Therapeutics Inc. - Sanofi S.A. - St. Jude Medical Inc. - UCB S.A. - Valeant Pharmaceuticals International Inc. - Zalicus Inc. For more information visit http://www.researchandmarkets.com/research/bj...lobal_pain
Zalicus to Present at AACR 2014 Annual Meeting
Business Wire - Tue Apr 01, 7:30AM CDT
Zalicus Inc. (Nasdaq Global Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that a poster developed in collaboration with colleagues from Eisai Inc. and a podium presentation with collaborators from Sanofi will be given at the American Association for Cancer Research (AACR) 2014 Annual Meeting which takes place April 5-9, 2014 in San Diego, CA. These preclinical data, which were generated in separate studies by leveraging the Zalicus combination High-throughput screening (cHTS(TM)) technology platform, demonstrate the potential to identify (or highlight) synergistic activity of the Eisai nontaxane eribulin and the Sanofi antibody drug conjugate SAR3419, through drug combinations.
Zalicus Reports Financial Results for the Fourth Quarter and Year-End 2013
Business Wire - Thu Mar 13, 6:30AM CDT
Zalicus Inc. (Nasdaq Capital Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today reported financial results for the fourth quarter and year ended December 31, 2013.
Canadian Forex Review: C$ Strengthens
Commodity News Service Canada - Commodity News Service Canada, Inc. - Wed Feb 12, 3:44PM CST
The Canadian dollar strengthened against the US dollar on Wednesday amid positive Chinese trade data, analysts said.
Hot Stock: Zalicus, Shares Gain 11.5% (ZLCS)
Comtex SmarTrend(R) - Wed Jan 22, 10:11AM CST
Zalicus (NASDAQ:ZLCS) is one of today's best performing low-priced stocks, up 11.5% to $2.14 on 3.1x average daily volume. Thus far today, Zalicus has traded 4.3 million shares, vs. average volume of 1.4 million shares per day. The stock has outperformed the Dow (25.9% to the Dow's -0.4%) and outperformed the S&P 500 (25.9% to the S&P's -0.1%) during today's trading.
3 Stocks Under $10 in Breakout Territory
at The Street - Wed Jan 22, 6:00AM CST
These under-$10 stocks are within range of triggering major breakout trades.
Traders Get Bullish on Shares of Zalicus, Shares Up 8.6% (ZLCS)
Comtex SmarTrend(R) - Fri Jan 17, 12:47PM CST
Zalicus (NASDAQ:ZLCS) is one of today's best performing low-priced stocks, up 8.6% to $1.76 on 1.1x average daily volume. Zalicus has traded 1.5 million shares thus far today, vs. average volume of 1.4 million shares per day. The stock has outperformed the Dow (8.6% to the Dow's 0.3%) and outperformed the S&P 500 (8.6% to the S&P's -0.2%) during today's trading.
Preliminary Results, Conferences, Stock Price Movements, and Acquisitions - Research Report on Community Health, ArthroCare, NuPathe, Zalicus, and Neogen
PR Newswire - Mon Jan 13, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
5 Stocks Under $10 Set to Soar
at The Street - Fri Jan 10, 6:00AM CST
These under-$10 stocks look ready to trade higher from current levels.
Biotech Trading 2014 Starts Hot, But Surprise, Last Year Was Even Better
at The Street - Thu Jan 09, 10:13AM CST
The biotech sector has jumped off to a strong start to 2014, with today's blockbuster move in Intercept Pharma offering a big assist. I know it's ridiculously early to make any sort of definitive judgment, but I wondered how the first days of biotech...
5 Stocks Poised for Breakouts
at The Street - Fri Jan 03, 2:19PM CST
These stocks look ready to break out and trade higher from current levels.
(0)
(0)Scroll down for more posts ▼